Optilume BPH Catheter System Provides Sustained Benefits
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 18, 2023 -- For men aged 50 years or older with symptomatic benign prostatic hyperplasia (BPH) and a prostate size between 20 and 80 g, minimally invasive surgery with the Optilume BPH Catheter System provides sustained improvements in obstructive symptoms and flow rate, according to a study published in the September issue of The Journal of Urology.
Steven A. Kaplan, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned men aged 50 years or older with symptomatic BPH and a prostate size between 20 and 80 g to receive treatment with Optilume BPH or a sham surgical procedure (100 active, 48 sham) at 18 centers in the United States and Canada.
The researchers found that at one year after treatment, participants randomly assigned to Optilume BPH had a reduction in the International Prostate Symptom Score of 11.5 ± 7.8 points compared with a reduction of 8.0 ± 8.3 points in the sham arm at three months. Treatment with Optilume BPH improved the flow rate, with improvement of +10.3 mL/s from baseline to one year.
"This minimally invasive treatment represents an attractive option to patients looking to maintain sexual function while achieving durable symptom relief and improved flow," the authors write.
The study was funded by Urotronic, which manufactures the Optilume BPH Catheter System.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Benign Prostatic Hyperplasia Risk Increased for Patients With Chronic Prostatitis
WEDNESDAY, April 3, 2024 -- Patients with chronic prostatitis (CP) have an increased risk for developing benign prostatic hyperplasia (BPH), according to a study published online...
Disparities in Transgender Prostate Screening Uptake Driven by Clinicians
FRIDAY, Feb. 23, 2024 -- Clinician recommendations are the most significant factor in driving prostate-specific antigen (PSA) screening in transgender women, according to a study...
Risk for Benign Prostatic Hyperplasia Increased for Patients With Gout
WEDNESDAY, Jan. 31, 2024 -- Patients with gout, especially those younger than 60 years, have an increased risk for benign prostatic hyperplasia (BPH), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.